GlassScriptPhysician profile
Douglas G Barstow
NPI 1326166273
$8,400.82
in general payments reported to CMS, 2019-2025
37 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $250 · 2021: $856 · 2022: $1,719 · 2023: $1,577 · 2024: $1,565 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Education: $46.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.69 |
| Education | $46.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,306.67 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,430.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $923.99 | 2021-2025 | Dupixent |
| Amgen INC. | $481.84 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $343.72 | 2020-2025 | Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $303.11 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $269.28 | 2025 | Neffy |
| Csl Behring | $265.73 | 2019-2025 | Hizentra, Haegarda |
| Alk-Abello, INC | $246.02 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Genzyme Corporation | $245.87 | 2019-2025 | |
| Kaleo, INC. | $224.44 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $182.94 | 2021-2025 | Panzyga, Cutaquig |
| Teva Pharmaceuticals USA, INC. | $123.78 | 2019 | |
| Genentech USA, INC. | $111.68 | 2019-2025 | Xolair |
| Leo Pharma INC. | $108.60 | 2024-2025 | Adbry |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $93.55 | 2020-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $82.39 | 2021 | |
| Grifols USA, LLC | $81.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.32 | 2021-2025 | |
| Ionis Pharmaceuticals, INC. | $54.23 | 2025 | Dawnzera |
| Abbvie INC. | $49.24 | 2022 | |
| Aimmune Therapeutics, INC. | $44.21 | 2022 | |
| Blueprint Medicines Corporation | $42.78 | 2024-2025 | Ayvakit |
| Hospira, INC. | $36.12 | 2024 | |
| Pfizer INC. | $35.50 | 2023-2024 | |
| Inspire Medical Systems, INC. | $30.15 | 2025 | Inspire |
| Organon LLC | $28.04 | 2025 | Vtama |
| Insmed, INC. | $23.04 | 2025 | Arikayce |
| Kedrion Biopharma, INC. | $19.97 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Optinose US, INC. | $19.61 | 2025 | |
| Lilly USA, LLC | $19.23 | 2024 | Ebglyss |
| Galderma Laboratories, L.P. | $18.70 | 2024 | |
| Uswm, LLC | $18.00 | 2021 | |
| Hikma Pharmaceuticals USA | $16.72 | 2023 | Ryaltris |
| Shire North American Group INC | $16.01 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.62 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Barstow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.